AI-Enabled Cancer Therapy Personalization
Artera was founded on the idea that cutting edge technology can be used to completely transform the medical field. The company has developed an application called the ArteraAI Prostate Test that uses predictive Artificial Intelligence to personalize care for people suffering from prostate cancer. The AI tool learns from patient-level clinical data and unannotated pathology slides to prognosticate long-term outcomes. Using five NRG Oncology Phase III randomized clinical trials, Artera has trained and validated prognostic biomarkers in localized prostate cancer. The company is led by Dr. Andre Esteva, who previously served as Head of Medical AI at Salesforce.